恩沃利单抗注射液 | China Drugs ListEnvafolimab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 适用于不可切除或转移性微卫星高度不稳定(MSI-H)或错配修复基因缺陷型(dMMR)的成人晚期实体瘤患者的治疗,包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。For adults with unresectable or metastatic MSI-H or dMMR advanced solid tumors, including advanced colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan treatment; and other advanced solid tumors that have progressed after prior treatment and have no satisfactory alternative treatment.
- 适应症来源与口径
- 来源日期： 2026. 适应症反映所引用的历史批准范围，不是截至2026年的完整适应症。Source date(s): 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
- 说明书信息局限
- 尚未取得可核实的完整药品说明书。现有批准记录或国家医保局申报资料支持所示适应症；最新完整范围尚待确认。A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.